Platform

Broad Applications Across Some of Today’s Most Virulent Diseases

While immuno-oncology remains our primary development focus, collaborations with partners like Leidos and the University of Edinburgh’s Center for Immunity, Infection and Evolution (CIIE), allow us to expand the use and potential value in infectious diseases.

The breadth and depth of our platform can enable us to target some of the most hard-to-address diseases in this space, including public health threats and indications with limited or no treatment options, such as RSV, virulent malaria, bioterrorism threats and the Zika virus.

Recent progress includes:

• IMV has an ongoing preclinical collaboration with top researchers from CIIE to address the most virulent form of malaria, which is the most likely to result in death and for which no preventive approach exists. Positive preclinical results from this research were presented at the 2016 World Vaccine Congress.
• A second malaria-focused project is underway with Leidos, funded through their contract with the US Agency for International Development (USAID). This collaboration is focused on identifying adjuvant and antigen combinations that are protective against malaria and to formulate these candidates in our platform for potential clinical testing.
• In 2016, we entered the global race to address the Zika virus by collaborating with Leidos to combat the Zika virus. Leidos will utilize its Virtual Pharmaceutical Development Program to lead an antigen discovery and development team to identify the best candidates for preventing Zika virus infection. Once these candidates are identified, we will formulate the new antigens in our platform for preclinical testing.

Our delivery platform has been shown in multiple studies to produce strong, high-quality immune responses with a tolerable safety profile across a range of infectious diseases, and to have the potential to produce these specific and sustained immune effects from a single dose.

Other novel characteristics of agents based on our platform, including the flexibility to work with almost any antigen or adjuvant and the scalability of off-the-shelf manufacturing, have the potential to eliminate drug development barriers, bringing stronger treatments to markets faster in areas of high unmet medical needs.